MARCIA UCHOA DE REZENDE
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Ortopedia e Traumatologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/41 - Laboratório de Investigação Médica do Sistema Músculoesquelético, Hospital das Clínicas, Faculdade de Medicina
LIM/41 - Laboratório de Investigação Médica do Sistema Músculoesquelético, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject FOUR-YEAR FOLLOW-UP OF A TWO DAY EDUCATIONAL PROGRAM ABOUT OA IN BRAZIL(2020) SILVA, J. Da; REZENDE, M. De; OCAMPOS, G.; SPADA, T.; FRANCISCO, L.; SANTOS, H. Dos; FARIAS, F.; SILVA, C. Da; CERNIGOY, C.; GREVE, J.; CIOLAC, E.conferenceObject DURING TWO YEARS, WHAT IS THE DIFFERENCE BETWEEN AN EXCLUSIVE TWO-DAY EDUCATIONAL PROGRAM ON OA AND A PROGRAM THAT ADDS MULTIMODAL ATTENTION FOR 6 MOTHS IN THE TREATMENT OF OA?(2020) REZENDE, M. U.; OCAMPOS, G.; BRITO, N. R.; SABINO, F. F.; SILVA, C. C.; CERNIGOY, C. H.; STRUTZ, C.; SILVA, J. R.; SPADA, T. C.; SILVA, M. M.; CASTRO, D.; SANTOS, H. P.; SOUZA, R. A.; FRANCISCO, L. S.; CAMARGO, O. P.conferenceObject MULTIMODAL OA TREATMENT PROGRAM REDUCES BMI(2020) REZENDE, M. De; OCAMPOS, G.; BRITO, N.; FARIAS, F.; SILVA, C. Da; CERNIGOY, C.; STRUTZ, C.; SILVA, J. Da; SPADA, T.; SILVA, M.; CASTRO, D.; SANTOS, H. Dos; SOUZA, R.; FRANCISCO, L.; CAMARGO, O. DeconferenceObject CASE REPORT: ROLE OF YTRIUM IN THE TREATMENT OF REFRACTORY SYNOVITIS IN OA(2020) REZENDE, M. De; OCAMPOS, G.; CAMARGO, O. DeconferenceObject OSTEOARTHRITIS OF THE HAND: THE USE OF JOINTS PROTECTION, ASSISTIVE TECHNOLOGY WITH AND WITHOUT EXERCISES(2020) SCARCELLA, D.; SILVA, T. Da; MASSETTI, T.; LUZO, M.; OCAMPOS, G.; REZENDE, M. De; LACMAN, S.; MONTEIRO, C.conferenceObject FOUR-YEAR FOLLOW-UP OF PARQVE STUDY - A TWO DAY EDUCATIONAL PROGRAM ABOUT OA IN THE BRAZILIAN POPULATION: IMPROVED FUNCTIONAL CAPACITY, QUALITY OF LIFE AND PHYSICAL ACTIVITY LEVELS(2020) REZENDE, M. U.; SILVA, J. R.; SPADA, T. C.; FRANCISCO, L. S.; SANTOS, H. P.; FARIAS, F. S.; SILVA, C. C.; CERNIGOY, C. H.; GREVE, J. D.; CIOLAC, E. G.- IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20(2020) REZENDE, Marcia Uchoa De; GURGEL, Henrique Melo Campos; OCAMPOS, Guilherme Pereira; CAMPOS, Gustavo Constantino De; FRUCCHI, Renato; PAILO, Alexandre Felicio; PASQUALIN, Thiago; VICENTE, Jose Ricardo Negreiros; CAMARGO, Olavo Pires DeObjective: To verify whether the use of Hylan G-F20 improves saline lavage and triamcinolone injection results in the treatment of hip osteoarthritis (HOA). Methods: 82 patients with HOA categorized as grades II and III severity, according to Kellgren and Lawrence criteria, were randomized into the groups: lavage and triamcinolone (G0); lavage, triamcinolone, and 2 mL of hylan G-F20 (01); lavage, triamcinolone, and 4mL of hylan G-F20 (02); lavage, triamcinolone, and 6mL of hylan G-F20 (03). The VAS, range of motion (ROM), WOMAC, and Lequesne questionnaires were administered at baseline, one, three, six, and twelve months post-injection. Results: All groups showed clinically relevant improvements (> 20%) between baseline and first month post-injection, maintaining subjective results throughout the study period (p < 0.001). We found no differences between groups in any subjective evaluations (p > 0.05, for all). G2 and G3 obtained improved flexion results up to a year (p = 0.028). Hylan groups presented an improved external rotation since the first postoperative month and maintained the results up to a year (01, p = 0.041; G2, p = 0.007), whereas G0 showed no improvement (p = 0.336). Conclusion: Hip lavage and triamcinolone injection, with or without the use of hylan, improves pain, function, and quality of life up to a year in HOA. Hylan may improve ROM up to one year.
- Target-based approach for osteoarthritis treatment(2020) CAMPOS, Gustavo C. de; TIEPPO, Antonio M.; JR, Cyro S. de Almeida; HAMDAN, Paulo C.; ALVES, Wilson M.; REZENDE, Marcia U. deThere is still no definitive treatment for knee osteoarthritis (OA). We are certainly far from a consensus on the best form of treatment or on an effective treatment recommendation. There are reasons for the current equivocal treatment recommendations in the face of this very serious health problem. The greatest of these reasons, undoubtedly, is the great complexity of the factors involved in the development and progression of knee OA and the complex pathophysiology including mechanical, inflammatory, metabolic, post-traumatic, molecular, genetic, and psychological changes. For several years, an attempt has been made to correlate different patient phenotypes to different patterns of response to treatment, thus creating the possibility of developing specific treatments for certain groups of patients and theoretically allowing better treatment efficacy. However, in practice we still find totally different responses and evolutions even in individuals belonging to the same phenotype. Thus, classification by phenotypes, despite being an advance, is not sufficient. The present article proposes a fragmented look at each of the many factors or targets involved in the genesis and evolution of OA. Therefore, we propose not the treatment of OAper sebut the management of an individual set of targets to achieve personalized OA management. We believe that, paradoxically, by fragmenting the view of the disease we will be able to treat our patients more holistically in an individualized way.